Using a granulocytopenic murine model, we evaluated the efficacy of cefoperazone plus sulbactam against disseminated infection due to isolates of 13-lactamase-producing, cefoperazone-resistant (MIC, 250 ,g/ml)
Gram-negative bacteria of the family Enterobacteriaceae and Pseudomonas aeruginosa are important pathogens during chemotherapy-induced granulocytopenia in cancer patients. These microorganisms are generally susceptible to beta-lactam drugs, such as cefoperazone, ceftazidime, and imipenem, that are commonly used as initial therapy during febrile neutropenia. Occasionally, however, organisms resistant to broad-spectrum beta-lactam agents are encountered (2) , and inappropriate initial therapy in such instances is likely to result in a poor outcome. As antimicrobial resistance among bacteria becomes more prevalent, there is an ever-increasing need for more effective antimicrobial agents.
Bacterial 3-lactamase production is the most common mechanism of resistance among gram-negative bacteria. Sulbactam is a semisynthetic beta-lactam sulfone compound that can irreversibly bind to clinically prevalent chromosome-and plasmid-mediated P-lactamases, thus rendering these enzymes ineffective (8) . The combination of cefoperazone and sulbactam has been shown to be remarkably active in vitro against cefoperazone-resistant gram-negative bacteria, including P. aeruginosa (2, 3, 13 Infection. The cefoperazone-resistant isolate of E. coli was grown on a cell-culture rotator to the log phase in MuellerHinton broth at 37°C for 4 h. The broth was centrifuged at 17,500 x g for 10 min, and the centrifuged organisms were resuspended in normal saline. Using a spectrophotometer, we adjusted the inoculum chosen for the experiment to 4 x 108 CFU/ml. (Preliminary experiments were done to determine the optimal size of the inoculum of E. coli adequate to cause death in >75% of untreated animals within 72 h of infection.) The inoculum of E. coli was introduced intraperitoneally into the mice on the second day of neutropenia.
An identical experiment was carried out with cefoperazone-resistant P. aeruginosa as the infecting organism. The inoculum used, after testing in preliminary experiments, was 4.5 x 106 CFU/ml. Therapy. Antibiotic treatment was begun within 2 h of infection. The agents used were cefoperazone at 700 mg/kg of body weight and cefoperazone plus sulbactam at 700 mg plus 350 mg. Preliminary experiments had been done with mice to determine the dosing schedules for cefoperazone and cefoperazone plus sulbactam that would produce peak levels comparable to those in humans. The mice were divided into three groups: group A-infected, untreated mice (controls); group B-infected mice treated with cefoperazone; and group C-infected mice treated with cefoperazone plus sulbactam. The drugs were given subcutaneously every 8 h for 3 days. Control mice were given subcutaneous injections of normal saline as a placebo.
Assessment of responses. Serum antibiotic levels in blood specimens drawn after the third dose of antibiotic were determined. High-pressure liquid chromatography was used for the drug assay (Biopharmaceutical Reference Laboratory, Houston, Tex. 
RESULTS
Antibiotic susceptibility and 13-lactamase production. The E. coli and P. aeruginosa isolates examined were cefoperazone resistant (MIC, 250 ,ug/ml) but susceptible to the combination of cefoperazone and sulbactam. The MICs and MBCs of cefoperazone in the combination were 3.2 and 6.3 ,ug/ml for E. coli and 6.3 and 12.5 ,ug/ml for P. aeruginosa.
The respective MICs of cefotaxime, tobramycin, imipenem, and ciprofloxacin were 0.1, 100, 0.04, and <0.05 ,ug/ml for E.
coli and >100, 6.2, 0.78, and 0.10 ,g/ml for P. aeruginosa. (i) Granulocytopenia. The mice became granulocytopenic after the second dose of cyclophosphamide. The total duration of granulocytopenia was 5 days in all three groups. Organisms were inoculated into mice on the second day of granulocytopenia.
(ii) Serum antibiotic levels. In experiments with E. coli, the mean peak cefoperazone concentrations were 274 ,g/ml for the single-drug group and 247 ,ug/ml for the combinationdrug group. For the latter group, the mean peak sulbactam level was 125 p,g/ml. In experiments with P. aeruginosa, the mean peak cefoperazone concentrations were 255 and 236 ,ug/ml for the single-and combination-drug groups, respectively, and the mean peak sulbactam level for the latter group was 168 ,ug/ml.
(iii) Survivors. Figure 1 shows the survival curves for mice in experiments with E. coli and P. aeruginosa. Significant differences in survival at 48 and 72 h of therapy were noted among the three groups in the experiment with P. aeruginosa (P < 0.001). At 72 h of therapy, none of the control mice were alive, while 10 and 50% of the cefoperazonetreated and cefoperazone-plus-sulbactam-treated mice, re- spectively, were alive. With E. coli, no significant difference in survival was noted among the groups; however, an improved trend in survival was observed for drug-treated mice. The survival rates were 73% for the cefoperazoneplus-sulbactam-treated group, 46% for the cefoperazonetreated group, and 25% for controls.
(iv) Quantitative cultures. Table 1 shows colony counts for E. coli and P. aeruginosa in the blood, liver, and spleen of control and drug-treated mice. Despite a smaller inoculum of P. aeruginosa, larger numbers of P. aeruginosa than of E. coli were found in the blood, liver, and spleen. All three sites showed markedly smaller numbers of organisms in drugtreated mice than in control mice. Highly significant differences among the three groups (control mice and cefoperazone-and cefoperazone-plus-sulbactam-treated mice) were noted (P < 0.0001) in experiments with E. coli and P. aeruginosa. Pairwise colony count comparisons in the experiment with E. coli were all highly significant (P < 0.0001), except for colony count comparisons for the blood, liver, and spleen between control mice and cefoperazone-treated mice. In the experiment with P. aeruginosa, the difference in colony counts in the blood between control mice and cefoperazone-treated mice was not significant. However, colony counts in the liver and spleen of control versus cefoperazone-treated mice were significantly different (liver, P < 0.05; spleen, P < 0.02). All other pairwise comparisons for the P. aeruginosa experiment were highly significant (P < 0.005).
DISCUSSION
Using a granulocytopenic murine model, we clearly demonstrate in the present study that the addition of sulbactam to cefoperazone improves the efficacy of cefoperazone against infection due to cefoperazone-resistant bacteria. The previously noted in vitro superiority of the two-drug combination (3) was confirmed in this animal study. Infected mice treated with cefoperazone plus sulbactam showed improved survival as well as fewer microorganisms in the blood and in the organs examined at autopsy. Serum antibiotic levels achieved in this experiment were comparable to those achieved clinically in humans.
The primary reason for the enhanced action of cefoperazone plus sulbactam appears to be 3-lactamase inhibition by sulbactam. The latter drug is very active against RichmondSykes class I (chromosome-mediated), III (plasmid-mediated), and V (PSE and OXA) P-lactamases (12) . In addition, sulbactam in combination with penicillins has been shown to be effective against bacteria that do not produce 3-lactamases (12, 17) . For explanation of such activity, secondary mechanisms of action of sulbactam have been suggested. These include its affinity for binding to penicillin-binding protein Ia in cell walls of bacteria and its augmenting effect on the oxidative mechanism of polymorphonuclear leukocytes (11, 16) . The former action produces morphologic changes in bacteria, making the organisms more readily susceptible to phagocytosis, and the latter action may result in an increased bactericidal capacity of polymorphonuclear leukocytes. Such modes of action of sulbactam may explain the improved activity of cefoperazone plus sulbactam against E. coli and P. aeruginosa observed in this study.
Our animal model is similar to models described by others (4, 5) . Unlike the previous investigators, we inoculated the microorganisms intraperitoneally to produce disseminated infection. Although a comparatively smaller inoculum of P. aeruginosa was used to produce infection, larger numbers of P. aeruginosa than of E. coli were consistently isolated at all sites examined, suggesting a higher level of virulence of pseudomonas in the neutropenic setting.
The advantages of the combination of cefoperazone plus sulbactam over cefoperazone alone include a prolonged half-life, a prolonged postantibiotic effect, and a broadened spectrum of activity against microorganisms, including gram-negative bacilli, gram-positive cocci, and anaerobes. (3, 10). The combination of cefoperazone plus sulbactam has been shown to be clinically effective in the treatment of infections in immunocompetent hosts as well as those with concomitant hematologic malignancies (7, 9) . In an open, noncomparative trial, the drug combination was noted to be effective in profoundly granulocytopenic patients with serious infections, including sepsis and pneumonia (7) . A response rate of 44% was seen for infected patients with persistent profound granulocytopenia. At present, there are data to support the use of cefoperazone, ceftazidime, and imipenem as monotherapeutic agents in the treatment of febrile granulocytopenic patients (14, 15, 19) . Encouraging preliminary results are available from three comparative studies examining the efficacy of cefoperazone plus sulbactam in the treatment of infected, neutropenic cancer patients (1, 6, 18) . With the present information, the combination of cefoperazone plus sulbactam should be considered for addition to the list of agents available for use during chemotherapy-induced granulocytopenia. This combination, if proven useful, may be reserved for the treatment of patients with known or suspected resistant gram-negative bacterial infections.
